ASC30

DRUG2 trials

Sponsors

Ascletis Pharma (China) Co. Ltd., Ascletis Pharma (China) Co., Limited

Conditions

Obesity or Overweight with Type 2 Diabetes MellitusWeight Management

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

CompletedNCT06680440

Ascletis Pharma (China) Co., LimitedWeight Management

Start: 2024-08-26End: 2025-04-03Updated: 2025-05-20

Phase 3

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants with Obesity or Overweight with Type 2 Diabetes Mellitus (AURORA-2)

Not yet recruitingCTIS2026-526336-39-00

Ascletis Pharma (China) Co. Ltd.Obesity or Overweight with Type 2 Diabetes Mellitus

Target: 320Updated: 2026-09-17